- Open Access
Chitosan microparticles loaded with yeast-derived PCV2 virus-like particles elicit antigen-specific cellular immune response in mice after oral administration
© Bucarey et al.; licensee BioMed Central Ltd. 2014
Received: 13 March 2014
Accepted: 18 August 2014
Published: 20 August 2014
Porcine circovirus type 2 (PCV2)-associated diseases are a major problem for the swine industry worldwide. In addition to improved management and husbandry practices, the availability of several anti-PCV2 vaccines provides an efficient immunological option for reducing the impact of these diseases. Most anti-PCV2 vaccines are marketed as injectable formulations. Although these are effective, there are problems associated with the use of injectable products, including laborious and time-consuming procedures, the induction of inflammatory responses at the injection site, and treatment-associated stress to the animals. Oral vaccines represent an improvement in antigen delivery technology; they overcome the problems associated with injection management and facilitate antigen boosting when an animals’ immunity falls outside the protective window.
Chitosan microparticles were used as both a vehicle and mucosal adjuvant to deliver yeast-derived PCV2 virus-like particles (VLPs) in an attempt to develop an oral vaccine. The physical characteristics of the microparticles, including size, Zeta potential, and polydispersity, were examined along with the potential to induce PCV2-specific cellular immune responses in mice after oral delivery.
Feeding mice with PCV2 VLP-loaded, positively-charged chitosan microparticles with an average size of 2.5 μm induced the proliferation of PCV2-specific splenic CD4+/CD8+ lymphocytes and the subsequent production of IFN-γ to levels comparable with those induced by an injectable commercial formulation.
Chitosan microparticles appear to be a safe, simple system on which to base PCV2 oral vaccines. Oral chitosan-mediated antigen delivery is a novel strategy that efficiently induces anti-PCV2 cellular responses in a mouse model. Further studies in swine are warranted.
Porcine circovirus-associated diseases (PCVAD) are a major problem affecting the productivity of the swine industry, resulting in considerable losses worldwide .
Porcine circovirus type 2 (PCV2) is thought to be the major causative agent of post-weaning multisystemic wasting syndrome (PMWS), a disease characterized by severe immunosuppression in the porcine host. The latest evidence suggests that PCV2-induced immune disorders are caused by silencing plasmacytoid dendritic cell responsiveness to pathogen-associated danger signals .
Consequently, PCV2 is also associated with many other conditions, including respiratory disease complex, reproductive failure, porcine dermatopathy and nephropathy syndrome (PDNS), congenital tremor, necrotizing tracheitis, and exudative epidermitis . These diseases are known as PCVAD or PCV2-associated diseases, a name that the American Association of Swine Veterinarians (AASV) uses to group together all diseases attributed to PCV2, including PMWS .
In addition to improved management and husbandry (e.g., better hygiene, less overcrowding, and better ventilation), anti-PCV2 vaccines are an efficient method of reducing both the impact of the disease and the subsequent economic costs; therefore, the worldwide demand for anti-PCV2 vaccines is high .
At present, five vaccines against PCV2 have been introduced into the international market. Three of these contain PCV2 capsid protein, which is expressed in baculovirus as an immunogenic virus-like particle antigen, and two contain inactivated PCV2 virions or a PCV2/PCV1 chimera . In all cases, reports from field trials suggest that commercially available PCV2 vaccines make a significant contribution to reduced mortality and improved pig growth on PMWS-affected farms, thereby reducing the economic impact of PCVAD on pig production worldwide .
We have long sought to develop an oral PCV2 vaccine for use by the swine industry. Oral administration should be more effective and reduce the indirect costs associated with injectable products. Developing injectable vaccines is laborious, time-consuming and expensive, and their administration is stressful for the animals and the products often induce inflammatory responses at the injection site . On the other hand, oral vaccines, which can be administered via food or water, represent an improvement in antigen delivery technology by enabling farmers to boost an animal’s immunity when it falls outside the protective window. This makes oral immunization procedures better suited for mass administration . However, increasing the mucosal immunogenicity of oral vaccines without compromising safety and tolerability is the holy grail of the vaccine industry . Furthermore, antigen digestion at mucosal sites is a factor that limits successful vaccine development; thus recent studies have aimed to microencapsulate different antigens within natural polymers, such as a chitosan, as a vehicle for the delivery of mucosal vaccines [10, 11].
Chitosan has well-defined properties, including good bioavailability and biocompatibility, low cost, and an ability to open intracellular tight junctions; therefore, it may be a suitable polymer for use as a delivery vehicle for oral vaccines . Moreover, functionalized forms of chitosan have attracted considerable interest due to improved mucoadhesivity, permeability, stability, and controlled/extended antigen release profiles at mucosal sites .
Recent evidence shows that oral administration of chitosan microparticles increases mucosal and systemic immune responses [12, 13]. The most recent oral vaccination studies show that antigen-loaded chitosan microparticles gain access to the gut-associated lymphoid tissue (GALT) by passing through the M-cells, which is a key step for inducing immune responses [14, 15]. Therefore, it appears that antigens carried by chitosan microparticles may be targeted specifically to the Peyer’s patches, thereby enhancing both local and systemic immune responses .
Here, we combined two strategic approaches to develop an experimental oral vaccine against PCV2. The vaccine was based on yeast-derived PCV2 virus-like particles (VLPs) microencapsulated with chitosan.
The PCV2 VLPs were produced using a synthetic optimized PCV2 cap gene sequence, which was expressed in Saccharomyces cerevisiae (S. cerevisiae). The expression and production of the Cap protein in yeast ensures that it is folded correctly and carries the appropriate post-translational modifications, thereby promoting auto-aggregation and the spontaneous formation of VLPs . In addition to inducing a more efficient immune response, such technology provides a new platform for the production of assembled PCV2 antigens.
Therefore, we set out to show that a new vaccine formulation based on raw yeast extracts containing PCV2 VLPs microencapsulated with chitosan would show immunogenic properties after oral administration. We hypothesized that oral administration of these chitosan microcapsules to mice would result in the delivery of VLPs to the GALT and elicit specific cellular responses against PCV2. A mouse model was used for these proof-of-concept experiments so that we could examine the immunological basis of the cellular response to oral immunization in detail and optimize the adjuvant effects of different chitosan-based formulations.
Encapsulating the PCV2 cap protein into chitosan microparticles
Next, we examined whether the yeast extracts to be microencapsulated contained the PCV2 Cap protein in the form of VLPs. Recombinant yeast extracts were purified by sucrose gradient centrifugation and examined under an electron microscope for the presence of nanoparticles, as previously described . The purified yeast extracts contained numerous nanoparticles with an average diameter of 18 nm and a morphology consistent with that of PCV2 VLPs (Figure 3C).
Chitosan microparticles loaded with yeast-derived PCV2 VLPs elicit antigen-specific cellular immune responses in mice after oral administration
We next examined whether these microparticles could induce the proliferation of antigen-specific lymphocytes isolated from the spleens of C57BL/6 mice after oral administration. For this purpose, splenocytes from orally immunized mice were isolated, re-stimulated with PCV2 virions in vitro, and then analysed by flow cytometry. The animals were divided into two groups (n = 3/group). Group 1 was immunized four times with the microparticle formulation (each immunization was separated by a 2 week interval), and the responses were compared with those of the non-immunized control group (group 2).
Flow cytometry analysis of splenic CD4+ and CD8+ cells inside the proliferation gate for mice immunized with the experimental oral PCV2 vaccine
29.37 ± 2.04
13.08 ± 4.83
48.60 ± 6.92
28.30 ± 8.83
38.16 ± 5.02
19.39 ± 5.27
63.26 ± 1.23
32.95 ± 1.14
Flow cytometry analysis of splenic CD4+ and CD8+ cells inside the proliferation gate for mice immunized with a commercial anti-PCV2 vaccine
31.38 ± 14.08
13.08 ± 4.83
50.03 ± 9.71
28.30 ± 8.83
39.43 ± 9.75
19.39 ± 5.27
63.29 ± 13.33
32.95 ± 1.14
IFN-γ induction after oral immunization
Here, we examined the oral vaccine concept in mice by studying the ability of chitosan-microparticles loaded with minimally purified yeast material enriched with PCV2 VLPs to elicit PCV2-specific cellular immune responses.
We previously showed that S. cerevisiae is a simple and safe system in which to generate virus-like PCV2 particles that induce PCV2-specific antibody responses in mice after oral administration . Therefore, we hypothesized that the successful initiation of anti-PCV2 mucosal responses after oral administration of yeast-expressed PCV2 Cap protein would depend on effective antigen delivery to mucosal sites, as well as upon correct folding and self-assembly of the antigen into VLPs. However, the adjuvant effect of the yeast cell constituents must also be taken into account. The latter assertion is supported by several reports showing that yeast cell wall components, mainly β-glucans, stimulate immune responses at mucosal sites [16–20].
On the other hand, the low stability of antigens exposed to the harsh conditions in the gastrointestinal tract, together with the induction of mucosal tolerance, make the induction of a reliable immune response through the oral delivery of assembled viral antigens very difficult. Thus, either large doses of antigens or very stable antigens are required. Therefore, to circumvent these issues, we encapsulated crude yeast extracts containing PCV2 VLPs with LMW chitosan, which improves both cell permeability and antigen stability. LMW chitosan also shows good adsorptive affinity for the PCV2 antigen, enabling it to be efficiently encapsulated into microparticles. Our rationale was based on the hypothesis that chitosan structurally resembles heparan sulfate, a glycosaminoglycan that is the natural receptor for PCV2 on host cells . Also, yeast-derived PCV2 VLPs have a negative Zeta potential (-12 mV, data not shown), which is opposite to that of chitosan microparticles (+8.19 mV); thus the chitosan and the PCV2 VLPs may be electrostatically attracted to each other.
It is also worth considering that part of the yeast-derived PCV2 antigen is located on the surface of the chitosan microparticle, enabling it to react specifically with the anti-PCV2 antibody. Thus, in this case, the microparticle formulation did not follow a core-shell stratification, meaning that the antigen is located within the core and the chitosan simply coats the surface. Therefore, when the antigen is microencapsulated by ionotropic gelation from a homogeneously dispersed polymer-antigen solution, a percentage of the antigen is retained in the matrix of the microparticle and the rest is displayed on the microparticle surface. Thus, the exposed antigen could be detected by immunofluorescence analysis using an anti-PCV2 antibody. This experiment confirmed that the PCV2 antigen was displayed on the microparticle surface (Figure 2A). Similar fluorescent data have been observed for other chitosan microparticle formulations .
Previous in vivo studies show that coating vaccine antigens with chitosan microparticles is the key to the success of mucosal immunization in mice. For example, van der Lubben et al. carried out extensive research into the use of chitosan microparticles for the delivery of mucosal vaccines and, in particular, their uptake by Peyer’s patches [10, 14, 15, 23]. They generated a human intestinal M-cell model by co-culturing intestinal epithelial cells (Caco-2) and GALT-derived B-lymphocytes (Raji cells), and then investigated the uptake of microparticles . They found that chitosan microparticles were taken up by M-like cells within the artificial epithelium; uptake by Peyer’s patches was also confirmed in a murine model . A common finding of these studies was that the size of microparticles is a key factor: efficient uptake by M-cells requires microparticles measuring < 10 μm in diameter if they are to reach the dome of the Peyer’s patches . Since chitosan is biodegradable, van der Lubben et al. also demonstrated that antigen was released from microparticles after their uptake by M-cells . In general, the behaviour of chitosan microparticles (both in vitro and in vivo) depends on physicochemical properties such as size, Zeta potential, and surface characteristics [10, 14, 15, 23].
The microparticles formulated and used in the present study measured ~2.5 μm in diameter, and showed very low polydispersity and a slight positive charge. Considering the effect of micro-carrier surface charges on cellular uptake, it is postulated that a positive Zeta potential is beneficial for M-cell transport because the M-cell membrane is negatively charged . In conclusion, both the size and Zeta potential of chitosan microparticles loaded with yeast-derived PCV2 VLPs are key factors that determine access to the GALT, thereby inducing the proliferation of PCV2-specific T-cells and the production of IFN-γ to levels comparable with those induced by an injectable commercial formulation.
This is the first report to explore cell-mediated immune response induced by oral administration of PCV2 antigen encapsulated within chitosan microparticles.
The functionalized (chemically modified) form of chitosan used for preparing microparticles has attracted considerable interest of late due to improved mucoadhesivity, permeability, stability, and a controlled/extended antigen release profile at mucosal sites [11, 26]. Therefore, our future studies will explore the use of these functionalized forms of chitosan for the preparation of microencapsulated PCV2 antigens and their optimization for use as oral vaccines.
Materials and methods
Transformation and expression of the PCV2 cap gene in S. cerevisiae and production of yeast extracts for microencapsulation
PCV2 cap gene expression was optimized as previously described by Bucarey et al. , with some modifications. Briefly, the pYES2::opt-cap plasmid was transformed into the expression host, S. cerevisiae INVSc1 (genotype: MATα his3Δ1 leu2 trp1-289 ura3-52/MATα his3Δ1 leu2 trp1-289 ura3-; phenotype: His-, Leu-, Trp-, Ura-) using the lithium acetate/single-stranded carrier DNA/polyethylene glycol method . Transformed colonies were cultured in selective autotrophic yeast nitrogen base (YNB) URA ̄ medium (6.7 g of YNB (US Biological, MA, USA), 5 g of casamino acid, 20 g of glucose, 0.03 g of tryptophan (Sigma-Aldrich Co., MO, USA), and 20 g of bactoagar (US Biological, Ma, USA) in 1,000 ml of distilled water) for 48 h at 30°C. The recombinant colonies were picked and transferred into 10 ml of liquid YNB URA ̄ medium and cultured overnight at 30°C until the optical density reached 0.6–0.7 at 600 nm (OD600). The cells were then harvested, washed twice with phosphate-buffered saline (PBS), and inoculated into 50 ml of induction medium (YNB URA ̄ medium containing 2% galactose (Sigma-Aldrich Co., MO, USA) instead of glucose) to a final OD600 of 0.1–0.3. The cells were then cultured at 30°C with shaking. The cells were induced for 24 h, harvested by centrifugation at 1,500 × g for 5 min at 4°C, and then resuspended in 5 ml of 0.6 M KCl. The cell walls were then digested with liticase (0.1 mg/ml; Sigma-Aldrich Co., MO, USA) at 37°C for 1 h. The resulting protoplasts were sonicated on ice (5 × 60 s cycles with 20 s intervals) using a 102C model Branson Digital Sonifier (Branson Ultrasonics Corporation, CT, USA) operated at 40% amplitude. The raw cell extracts were clarified by centrifugation at 1,500 × g for 5 min at 4°C and analysed by SDS-PAGE followed by Western blotting with a mouse anti-Cap PCV2-specific monoclonal antibody (isotype IgG2a; 1:100 dilution; Jeno Biotech Inc., Republic of Korea), as described by Bucarey et al. . The raw extracts (without clarification) were lyophilized and ground to produce the yeast powder used for microencapsulation into LMW chitosan (75–85% deacetylated; Sigma-Aldrich Co., MO, USA).
Chitosan and yeast-derived PCV2-antigen microencapsulation
Preparation of the vaccine formulation included the microencapsulation of the viral antigen to protect it and control its release at the mucosal level. Approximately 30 mg of PCV2 Cap protein was used for each microencapsulation. The amount was calculated by assuming that approximately 10% p/p of the dry weight of the recombinant yeast extract comprised PCV2 VLP (data obtained from a previous report ). The PCV2 VLP antigen was coated with LMW chitosan (Sigma-Aldrich, MO, USA) by ionotropic gelation as previously described , with some modifications. Briefly, 30 ml of LMW chitosan (1% w/v in 2.5% acetic acid) was mixed with 375 mg of dry raw yeast extract (S. cerevisiae/pYES2::opt-cap) with mechanical stirring (1510 rpm). The microencapsulation reaction was initiated by the drop-wise addition of 5 ml of sodium tripolyphosphate (TPP; 3 mg/ml) (Sigma-Aldrich, MO, USA) at a rate of approximately 1 ml/min (with constant stirring). The solution was then stirred for a further 20 min at room temperature.
The resulting microparticle suspension was centrifuged at 3,000 × g for 10 min. The efficiency of the microencapsulation process was 90–95% (estimated by subtracting the total amount of yeast-derived protein remaining in the supernatant from the initial amount of protein added). Protein concentrations were measured using the BCA™ protein assay kit (Pierce, Rockford, IL, USA). The pelleted microparticles were washed twice with Milli-Q water, lyophilized, weighed, and stored. Samples of the lyophilized microparticles were suspended in PBS (pH 7.0; final concentration, 35 mg/ml) and stored at 5°C. These samples were used to test PCV2 antigen delivery in vitro and to induce cellular immune responses in mice following oral administration.
Scanning electron microscopy, size estimation, and measurement of the Zeta potential of chitosan microparticles
Each microparticle formulation was examined under a scanning electron microscope (SEM; Tesla BS 343 operating at 15 KeV; ×3,300 magnification) to examine the morphology and size of the individual microparticles. Briefly, the freeze-dried microparticles were spread onto metallic discs and gold-coated (20 nm thick) using an EMS-550 automated sputter coater.
The Zeta potential of the chitosan microparticles was measured using a Zeta potential analyser (Zeta plus, Brookhaven Instruments Co., NY, USA). All Zeta potential measurements were determined at 25°C in an electric field of 11.00 V/cm. The size and polydispersity index were determined by light scattering using a multi-angle particle sizing option (90PLUS/BI-MAS, Brookhaven Instruments Co.). A stock solution of each chitosan microparticle sample (1.6 mg/ml in ultra-pure water) was used for both Zeta potential and particle size measurements. Ten millilitres of each solution were mixed with 10 ml of bi-filtered KCl (1 mM in ultra-pure water; pH 7).
Immunofluorescence microscopy of chitosan microparticles
For immunofluorescence microscopy, 10 mg of freeze-dried chitosan microparticles were blocked overnight in 200 μl of PBS/5% skim milk at 4°C and then incubated overnight at 4°C with a mouse anti-Cap PCV2-specific monoclonal antibody (isotype IgG2a, Jeno Biotech Inc.) diluted 1:100 in PBS/0.1% Tween-20 (PBST). After washing with PBST, the microparticles were incubated with FITC-conjugated goat anti-mouse IgG (H + L) (Kirkegaard & Perry Laboratories Inc.) for 1 h. After further washing, the microparticles were visualized under a Nikon Eclipse E400 fluorescence microscope interfaced to a PC running capture software (Nis-Element Br, Nikon).
Microparticles loaded with extracts of S. cerevisiae transfected with an empty plasmid (S. cerevisiae/ pYES2) were subjected to the same treatment and used as a negative fluorescence control.
PCV2 antigen loading and delivery efficiency of the chitosan microparticles
The release of PCV2 VLP from the chitosan microparticles was measured in Tris-HCl (pH 1). After antigen loading, the microparticles were resuspended in Tris-HCl to yield a 1% w/v suspension. Samples (200 μl) were then incubated at 90°C with gentle shaking. After 0, 5, 10, 15 and 30 min, the tubes were centrifuged (10,000 × g for 2 min). Samples of the supernatant (100 μl) were taken and the amount of non-bound PCV2 VLP was determined using the Dot blot method. Briefly, samples were transferred onto a nitrocellulose membrane using a Biodot™ microfiltration apparatus (Bio-Rad, CA, USA). The nitrocellulose membrane was then blocked overnight in 5% skim milk at 4°C and then incubated overnight at 4°C with a mouse anti-Cap PCV2-specific monoclonal antibody (isotype IgG2a, Jeno Biotech Inc.) diluted 1:100 in PBS/0.1% Tween-20 (PBST). After washing with PBST, the membrane was incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (H + L) (1:1,000 dilution; Kirkegaard & Perry Laboratories Inc.) for 1 h. After further washing, the signal was detected using 4-chloro-1-naphthol/H2O2 as directed by the manufacturer (Pierce, Rockford, IL, USA). The concentration of yeast-produced Cap protein was estimated by comparing the signal intensities of the blots with those of known concentrations of a highly purified 6xhis-Cap fusion protein as previously described .
Purification of yeast-derived PCV2 virus-like particles
Clarified yeast extract (500 μl) expressing PCV2 Cap protein was layered onto a discontinuous sucrose gradient (20–50%) and centrifuged at 80,000 × g for 18 h using a Beckman SW-28 rotor. The gradients were fractioned by puncturing the bottom of the centrifuge tube and collecting approximately ten fractions. The fraction densities were determined using a refractometer (32-G110e; Carl Zeiss Jena, Germany). Fractions with a density between 1.2 and 1.27 g/cm3 (three fractions in all) were pooled, and the presence of Cap protein was determined by SDS-PAGE. The VLP preparations were dialyzed against PBS and stored at −20°C until visualization by transmission electron microscopy (TEM).
Purification of the PCV2 6xhis-Cap protein
The complete PCV2 capsid protein gene was subcloned in a pQE80L expression vector (Qiagen, Inc., USA) via the SphI and KpnI restriction sites to generate an in-frame genetic fusion bearing a polyhistidine tag. The bacterial Cap protein was used to produce a purified 6xhis-Cap fusion protein for use as a PCV2 protein standard for blotting as described previously . Briefly, the recombinant E. coli strain, BL21 (Amersham), containing the pqE80L::cap plasmid was grown in Luria Broth medium (10 g l-1 yeast extract, 16 g l-1 tryptone, 5 g l-1 NaCl, 100 μg/ml ampicillin, pH 7.0) and induced for 5 h at 37°C with isopropylthio-b-D-thiogalactoside (IPTG) at a final concentration of 0.1 mM. The cells were pelleted and resuspended in lysis buffer (8 M Urea, 10 mM Tris, 100 mM NaH2PO4, 1% Triton X-100, pH 8.0) and then lysed by sonication on ice for two 60 s cycles using a Branson Digital Sonifier® operated at 10% amplitude. After centrifugation at 10,000 × g for 10 min at 4°C, the supernatant was loaded onto a Ni-NTA affinity column (Ni-NTA Purification System, Invitrogen, CA, USA) according to the manufacturer’s protocol. After washing twice with PBS, the Cap protein was eluted in elution buffer (50 mM Tris-HCl, 10 mM imidazole, pH 8.0) and collected. The collected samples were analysed by SDS-PAGE and Western blotting, as described below. The concentration of Cap protein was determined using a Coomassie (Bradford) Protein Assay Kit (Pierce, Rockford, IL, USA).
Transmission electron microscopy
Yeast-produced VLP preparations (20 μl) were diluted 1/10, adsorbed onto a carbon-coated copper grid, and incubated for 5 min. The grids were then dried using filter paper, negatively stained with 3% phosphotungstic acid (PTA) for 5 min, and viewed using a transmission electron microscope (Zeiss EM 109) operating at 80 kV.
Male C57BL/6 mice (5 weeks old) were obtained from the Faculty of Veterinary Sciences at the University of Chile. The animals were assigned to two experimental groups (n = 3 mice/group) and maintained in a temperature and light-controlled environment with access to food and water ad libitum. One group (group 1) was used to evaluate specific anti-PCV2 cellular responses against PCV2 virions after oral administration of chitosan microparticles loaded with raw extracts of S. cerevisiae expressing the yeast-optimized cap gene (S. cerevisiae/ pYES2::opt-cap). The second group comprising untreated (control) mice (group 2) was subjected to the same treatment regimen, but they received PBS alone.
Group 1 received four 200 μl doses of a solution containing 35 mg of chitosan microparticles dissolved in 1 ml of PBS (approximately 7 mg of microparticles per mouse) via oral gavage, with a 14 day interval between doses. The concentration of PCV2 Cap protein in each dose (approximately 300 μg) was determined by densitometric analysis of Dot blots generated using standard dilutions of known concentrations of a bacterially produced Cap-6 × his fusion protein. Group 2 received four 200 μl doses of PBS.
These immunization experiments were repeated twice under the same conditions; thus the total number of animals analysed was 12.
An additional control group (n = 3) was used to examine the immune response elicited by a commercially available PCV2 vaccine (Ingelvac® CircoFLEX™, Boehringer Ingelheim Vetmedica GmbH), which was administered subcutaneously. Briefly, 0.1 ml of formulated vaccine, containing approximately 100 μg of PCV2 antigen, was injected subcutaneously, followed by a booster immunization (with the same dose) 2 weeks later. A third and final immunization was performed 2 weeks after boosting .
Animals were sacrificed by an overdose of a mixture of isoflurane/O2. The experimental protocol was approved by the institutional animal bioethics committee as stipulated in the guide to the care and use of experimental animals of the Canadian Council on Animal Care.
Analysis of T-cell proliferation
Animals were euthanized on Day 42 of the experiment as described above, and the spleens were aseptically removed and ground through a sterile cuprous mesh into PBS. A suspension of individual cells was then obtained by repeated passage through a 21G syringe. The splenocytes were then centrifuged and resuspended in erythrocyte lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 1.3 mM EDTA). After washing with PBS, the cells were stained with CFSE (CellTrace™; CFSE Cell Proliferation Kit, Molecular Probes) as previously described , with some modifications. Briefly, cells (5 × 107) were incubated with 1 ml of PBS containing 10 μM CFSE at 37°C for 10 min. The cells were then washed twice with PBS/5% FBS (Foetal Bovine Serum) resuspended (at 2 × 106 cells/ml) in RPMI medium (Thermo Scientific™, MA, USA) supplemented with 10% FBS and then seeded into 96-well plates at a density of 4 × 105 cells/well. The stained splenocytes were then re-stimulated with PCV2 virions (10 TCID50 in 50 μl of MEM-α) obtained from PCV2-positive PK-15 cells (ATCC CCL-33) . Non-stimulated splenocytes were used as a negative control (vehicle). As a positive control for non-specific lymphocytic proliferation, splenocytes were incubated in 96-well plates coated with anti-CD3 antibodies (polyclonal stimulators). The cultures were incubated for 96 h and lymphocyte proliferation was examined by acquiring 100,000 events in a FACSCalibur® flow cytometer (Becton Dickinson Immunocytometry Systems, CA, USA). Data were analysed using Flowing Software, version 2.5.
Initially, the population of interest was defined by gating on SSC (cellular complexity) and FSC (cell size). The population of interest was further defined as viable mature and immature lymphocytes, as previously described . This population contained the highest percentage of CD3+ cells. Further population analysis was performed by gating on FSC and the CD4 or CD8 lymphocyte markers.
Measurement of IFN-γ secretion
A mouse IFN-γ enzyme-linked immunosorbent assay (ELISA) Kit (Thermo Fisher Scientific Inc, MA, USA) was used to measure the concentration of IFN-γ in T-cell culture supernatants according to the manufacturer’s instructions. Briefly, culture supernatants from splenocytes derived from immunized and controls mice were diluted 1:50 in PBS, and 100 μL of the resulting solution was added to triplicate wells of the ELISA plate. The absorbance was measured at 550 nm and at 450 nm in a Microplate Reader (Bio-Rad Instruments, CA, USA). The former value was then subtracted from the latter. A standard curve was constructed using a set of standards provided by the manufacturer and the experimental values were read off this curve.
The IFN-γ ELISA assay results were expressed as the mean ± standard deviation. Differences between groups were analysed by ANOVA with Tukey’s post-test. A p-value < 0.01 was considered significant. Analyses were performed using GraphPad Prism software.
This work was supported by grant (FONDECYT no. 11110135) from Chilean Council for Science and Technology (CONICYT). S.A. B. was additionally supported by grant ENLACE 06/2014 from Vicerrectoria de Investigación y Desarrollo, Universidad de Chile. We would like to thank Centrovet SA for help with flow cytometry.
- Beach NM, Meng XJ: Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2). Virus Res 2012, 164: 33-42. 10.1016/j.virusres.2011.09.041PubMedView ArticleGoogle Scholar
- Vincent IE, Carrasco CP, Guzylack-Piriou L, Herrmann B, McNeilly F, Allan GM, Summerfield A, McCullough KC: Subset-dependent modulation of dendritic cell activity by circovirus type 2. Immunology 2005, 115: 388-398. 10.1111/j.1365-2567.2005.02165.xPubMedPubMed CentralView ArticleGoogle Scholar
- Harding JC: The clinical expression and emergence of porcine circovirus 2. Vet Microbiol 2004, 98: 131-135. 10.1016/j.vetmic.2003.10.013PubMedView ArticleGoogle Scholar
- Segales J, Allan GM, Domingo M: Porcine circovirus diseases. Anim Health Res Rev 2005, 6: 119-142. 10.1079/AHR2005106PubMedView ArticleGoogle Scholar
- Tacker BWW, Francisco C, Schlueter R: Circumvent PCV vaccine: performance evaluation and serological studies update. Proceedings of the AASV Congress 2008, 1536-1548.Google Scholar
- Kristensen CS, Baadsgaard NP, Toft N: A meta-analysis comparing the effect of PCV2 vaccines on average daily weight gain and mortality rate in pigs from weaning to slaughter. Prev Vet Med 2011, 98: 250-258. 10.1016/j.prevetmed.2010.11.015PubMedView ArticleGoogle Scholar
- Bucarey SA, Noriega J, Reyes P, Tapia C, Saenz L, Zuniga A, Tobar JA: The optimized capsid gene of porcine circovirus type 2 expressed in yeast forms virus-like particles and elicits antibody responses in mice fed with recombinant yeast extracts. Vaccine 2009, 27: 5781-5790. 10.1016/j.vaccine.2009.07.061PubMedView ArticleGoogle Scholar
- Pavot V, Rochereau N, Genin C, Verrier B, Paul S: New insights in mucosal vaccine development. Vaccine 2012, 30: 142-154. 10.1016/j.vaccine.2011.11.003PubMedView ArticleGoogle Scholar
- Lavelle EC, O’Hagan DT: Delivery systems and adjuvants for oral vaccines. Expet Opin Drug Deliv 2006, 3: 747-762. 10.1517/17425247.3.6.747View ArticleGoogle Scholar
- van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Coos Verhoef J, Junginger HE: Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 2003, 21: 1400-1408. 10.1016/S0264-410X(02)00686-2PubMedView ArticleGoogle Scholar
- Islam MA, Firdous J, Choi YJ, Yun CH, Cho CS: Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review. Int J Nanomedicine 2012, 7: 6077-6093.PubMedPubMed CentralGoogle Scholar
- Jabbal-Gill I, Watts P, Smith A: Chitosan-based delivery systems for mucosal vaccines. Expet Opin Drug Deliv 2012, 9: 1051-1067. 10.1517/17425247.2012.697455View ArticleGoogle Scholar
- Le Buanec H, Vetu C, Lachgar A, Benoit MA, Gillard J, Paturance S, Aucouturier J, Gane V, Zagury D, Bizzini B: Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes. Biomed Pharmacother 2001, 55: 316-320. 10.1016/S0753-3322(01)00073-7PubMedView ArticleGoogle Scholar
- Van Der Lubben IM, Konings FA, Borchard G, Verhoef JC, Junginger HE: In vivo uptake of chitosan microparticles by murine Peyer’s patches: visualization studies using confocal laser scanning microscopy and immunohistochemistry. J Drug Target 2001, 9: 39-47. 10.3109/10611860108995631PubMedView ArticleGoogle Scholar
- van der Lubben IM, van Opdorp FA, Hengeveld MR, Onderwater JJ, Koerten HK, Verhoef JC, Borchard G, Junginger HE: Transport of chitosan microparticles for mucosal vaccine delivery in a human intestinal M-cell model. J Drug Target 2002, 10: 449-456. 10.1080/1061186021000038319PubMedView ArticleGoogle Scholar
- Soltanian S, Stuyven E, Cox E, Sorgeloos P, Bossier P: Beta-glucans as immunostimulant in vertebrates and invertebrates. Crit Rev Microbiol 2009, 35: 109-138. 10.1080/10408410902753746PubMedView ArticleGoogle Scholar
- Stubbs AC, Martin KS, Coeshott C, Skaates SV, Kuritzkes DR, Bellgrau D, Franzusoff A, Duke RC, Wilson CC: Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001, 7: 625-629. 10.1038/87974PubMedView ArticleGoogle Scholar
- Stuyven E, Cox E, Vancaeneghem S, Arnouts S, Deprez P, Goddeeris BM: Effect of beta-glucans on an ETEC infection in piglets. Vet Immunol Immunopathol 2009, 128: 60-66. 10.1016/j.vetimm.2008.10.311PubMedView ArticleGoogle Scholar
- Stuyven E, Verdonck F, Van Hoek I, Daminet S, Duchateau L, Remon JP, Goddeeris BM, Cox E: Oral administration of beta-1,3/1,6-glucan to dogs temporally changes total and antigen-specific IgA and IgM. Clin Vaccine Immunol 2010, 17: 281-285. 10.1128/CVI.00344-09PubMedPubMed CentralView ArticleGoogle Scholar
- Zanello G, Meurens F, Berri M, Salmon H: Saccharomyces boulardii effects on gastrointestinal diseases. Curr Issues Mol Biol 2009, 11: 47-58.PubMedGoogle Scholar
- Misinzo G, Delputte PL, Meerts P, Lefebvre DJ, Nauwynck HJ: Porcine circovirus 2 uses heparan sulfate and chondroitin sulfate B glycosaminoglycans as receptors for its attachment to host cells. J Virol 2006, 80: 3487-3494. 10.1128/JVI.80.7.3487-3494.2006PubMedPubMed CentralView ArticleGoogle Scholar
- Choi JS, Kim Y, Kang J, Jeong SY, Yoo HS: Electrospun chitosan microspheres for complete encapsulation of anionic proteins: controlling particle size and encapsulation efficiency. AAPS PharmSciTech 2013, 14: 794-801. 10.1208/s12249-013-9965-xPubMedPubMed CentralView ArticleGoogle Scholar
- van der Lubben IM, Verhoef JC, van Aelst AC, Borchard G, Junginger HE: Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer’s patches. Biomaterials 2001, 22: 687-694. 10.1016/S0142-9612(00)00231-3PubMedView ArticleGoogle Scholar
- Mitragotri S: Immunization without needles. Nat Rev Immunol 2005, 5: 905-916. 10.1038/nri1728PubMedView ArticleGoogle Scholar
- Jiang T, Singh B, Li HS, Kim YK, Kang SK, Nah JW, Choi YJ, Cho CS: Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. Biomaterials 2014, 35: 2365-2373. 10.1016/j.biomaterials.2013.11.073PubMedView ArticleGoogle Scholar
- Dunnhaupt S, Barthelmes J, Rahmat D, Leithner K, Thurner CC, Friedl H, Bernkop-Schnurch A: S-protected thiolated chitosan for oral delivery of hydrophilic macromolecules: evaluation of permeation enhancing and efflux pump inhibitory properties. Mol Pharm 2012, 9: 1331-1341.PubMedGoogle Scholar
- Gietz RD, Woods RA: Yeast transformation by the LiAc/SS Carrier DNA/PEG method. Methods Mol Biol 2006, 313: 107-120.PubMedGoogle Scholar
- Harlow EaL D: Antibodies: A Laboratory Manual. New York: Cold Spring Harbor Laboratory; 1998.Google Scholar
- Quah BJ, Parish CR: The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte proliferation. J Vis Exp 2010, 44: e2259.Google Scholar
- Dulac GC, Afshar A: Porcine circovirus antigens in PK-15 cell line (ATCC CCL-33) and evidence of antibodies to circovirus in Canadian pigs. Can J Vet Res 1989, 53: 431-433.PubMedPubMed CentralGoogle Scholar
- Salguero Erica PD, Angélica M, Gabriela D: Quantification by flow cytometry of CD4+, CD8+, CD19+ and CD14+ mouse splenocytes, obtained from four species used in Immunotoxicology’s studies. Rev Col Cienc Quím Farm 2007, 36: 44-54.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.